Heidi Overton, President Trump’s nominee for FDA Commissioner, recently faced a Senate hearing where she largely avoided expressing her own views on critical issues like vaccine policy and abortion access. This lack of clarity is concerning for those in the health and medicine sectors, as it creates uncertainty about the future direction of the agency. Novo Nordisk’s agreement to license Nanexa’s drug delivery technology, potentially enabling less frequent injections for obesity and diabetes drugs, signals a continued focus on patient convenience and improved treatment regimens.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views278
Ali NematiBlogUI.author_articles
